Table 1.
TLR4 rs10759931 and rs2737190 genotype distribution in patients with or without cognitive deficit following COVID-19
| TLR4-2604G>A (rs10759931) | N (86) | Cognitive deficit (%) | No cognitive deficit (%) | p value | OR (95% CI) | Adjusted p value for SDMT time |
|---|---|---|---|---|---|---|
| GG | 40 | 22 (55) | 18 (39) | 0.0234∗ | 1.91 (1.083–3.301) | 0.0129∗ |
| GA | 35 | 13 (32) | 22 (48) | 0.0209∗ | 0.50 (0.287–0.920) | |
| AA | 11 | 5 (13) | 6 (13) | >0.9999 | 1.00 (0.435–2.294) | |
| MAF (A) |
0.35 |
– |
– |
– |
– |
|
|
TLR4 -2272 A>G (rs2737190) |
N (83) |
Cognitive deficit (%) |
No cognitive deficit (%) |
p value |
OR (95% CI) |
|
| AA | 30 | 14 (37) | 16 (36) | 0.8832 | 1.04 (0.594–1.836) | 0.0809 |
| AG | 35 | 16 (42) | 19 (42) | >0.9999 | 1.0 (0.561–1.781) | |
| GG | 18 | 8 (21) | 10 (22) | 0.8633 | 0.94 (0.483–1.823) | |
| MAF (G) | 0.49 | – | – | – | – |
MAF, minor-allele frequency; OR, odds ratio; CI, confidence interval. Genotype frequency was analyzed by χ2 test (two tailed). Test time was included as a covariate in the logistic regression analyses. ∗Statistical significance (p < 0.05). The reference group in each of the analyses was the most prevalent genotype.